Avinger Inc
avinger.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 7, 2024. Its latest SEC filing is a 25-NSE from Jun 23, 2025.
10-Q for Q3 FY2024, filed Nov 7, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells image-guided catheters and imaging consoles for physicians treating peripheral artery disease; hospitals and medical centers are the buyers.
10-K for FY2023, filed Mar 20, 2024We are a commercial-stage medical device company that designs, manufactures, and sells real-time high-definition image-guided, minimally…View ↗
We design, manufacture, and sell a suite of products in the United States and select international markets. We are located in Redwood City…View ↗
We focus our direct sales force, marketing efforts and promotional activities on interventional cardiologists, vascular surgeons and…View ↗
How Did They Make Money?
Hospitals and medical centers buy consoles at delivery and acceptance and catheters and accessories when shipped, directly or through distributors; service contracts earn revenue over their term, and maintenance when work is completed.
10-K for FY2023, filed Mar 20, 2024The Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories…View ↗
Lightbox console sales: Provided all other criteria for revenue recognition have been met, the Company recognizes revenue for Lightbox…View ↗
Sales of disposables: Disposable revenues consist of sales of the Company’s catheters and accessories and are recognized when the product…View ↗
Service revenue: Service contract revenue consists of preventative maintenance, upgrades, and service contracts. Service contracts are…View ↗
For sales of disposables through distributors, the Company recognizes revenue when control of the product transfers from the Company to the…View ↗
$7.7M
-
10-K for FY2023, filed Mar 20, 2024
$7.7M ↗
Who Were Their Customers?
Hospitals and medical centers typically buy the products, directly or through distributors; physicians are the main users.
10-K for FY2023, filed Mar 20, 2024We focus our direct sales force, marketing efforts and promotional activities on interventional cardiologists, vascular surgeons and…View ↗
The Company’s revenues are derived from (1) sale of Lightbox consoles, (2) sale of disposables, which consist of catheters and accessories…View ↗
We focus our sales and marketing efforts primarily on the approximately 10,000 interventional cardiologists, vascular surgeons and…View ↗
10-K for FY2023, filed Mar 20, 2024
The Company’s accounts receivable are due from a variety of healthcare organizations in the United States and select international markets.…View ↗
Did Revenues Turn Into Profits?
No. It lost $18.3M in FY2023.
10-K for FY2023, filed Mar 20, 2024
−$16.6MView ↗
10-K for FY2023, filed Mar 20, 2024
−$18.3MView ↗
10-K for FY2023, filed Mar 20, 2024
−$14.4MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 7, 2024
−$3.7MView ↗
- ▼ −17% (Loss)
- vs −$4.5M in Q3 FY2023
-
Feb 10, 2025
Transferred substantially all assets through an assignment for creditors
The agreement transfers substantially all assets to an assignee; the CEO was terminated and the auditor ended its engagement.
Sources
8-K, filed Feb 10, 2025
Effective February 10, 2025, the Board (i) determined that the transfer of all or substantially all of the Company’s assets through an…View ↗
-
Jan 3, 2025
Shifted focus from PAD products to coronary blockage devices
Avinger ended PAD manufacturing and sales and plans to focus on research and development of devices for coronary artery blockages.
Sources
8-K, filed Jan 3, 2025
In an effort to preserve and more efficiently allocate resources, the Board of Directors (the “Board”) of Avinger, Inc. (the “Company”)…View ↗
Shrank. Revenue fell 16% in 4 years, from $9.1M in FY2019 to $7.7M in FY2023, about 4% a year.
Expanded catheter lineup
The latest report adds Tigereye ST for crossing arterial blockages and Pantheris LV for removing plaque in larger vessels; the older report described Tigereye and Pantheris products without those versions.
10-K for FY2020, filed Mar 11, 2021 10-K for FY2023, filed Mar 20, 2024
Who Did They Compete With?
Competes with Abbott Laboratories, AngioDynamics, Becton Dickinson, Boston Scientific, Cardinal Health, Cook Medical, Medtronic, Philips, and Cardiovascular Systems
10-K for FY2023, filed Mar 20, 2024Our products compete with a variety of products or devices for the treatment of PAD, including other CTO crossing devices, stents, balloons…View ↗
Loading...
